TG Therapeutics, Inc.
TG Therapeutics, Inc., a prominent biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for patients with B-cell malignancies and autoimmune diseases. Founded in 2012, the company has made significant strides in the industry, particularly with its unique approach to targeted therapies that leverage the power of monoclonal antibodies and small molecules. With a strong presence in the oncology and autoimmune sectors, TG Therapeutics has achieved notable milestones, including the advancement of its lead product candidates, which aim to improve treatment outcomes for patients. The company is recognised for its commitment to research and development, positioning itself as a leader in the biopharmaceutical landscape. Through its dedication to innovation, TG Therapeutics continues to make a meaningful impact on patient care and treatment options.
DitchCarbon Score
How does TG Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
TG Therapeutics, Inc.'s score of 25 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
TG Therapeutics, Inc.'s reported carbon emissions
TG Therapeutics, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as there are no available figures for their emissions in kg CO2e. Additionally, the company has not established any documented reduction targets or climate pledges. As of now, TG Therapeutics does not inherit emissions data from a parent company, nor does it have any cascading targets from related organisations. This lack of data and commitments places the company in a position where it may need to enhance its climate strategy to align with industry standards and expectations for sustainability. In the absence of specific emissions figures or reduction initiatives, it is crucial for TG Therapeutics to consider developing a comprehensive climate action plan to address potential environmental impacts and contribute positively to global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
TG Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
